Published in J Virol on October 11, 2006
Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med (2013) 3.41
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression. J Acquir Immune Defic Syndr (2014) 0.86
Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells. Eur J Immunol (2011) 0.80
NK Cell Influence on the Outcome of Primary Epstein-Barr Virus Infection. Front Immunol (2016) 0.76
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. Clin Exp Immunol (2009) 0.76
Genetic Causes of Human NK Cell Deficiency and Their Effect on NK Cell Subsets. Front Immunol (2016) 0.75
Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ. Oncotarget (2017) 0.75
High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults. PLoS One (2017) 0.75
Hepatitis C Virus and Human Cytomegalovirus-Natural Killer Cell Subsets in Persistent Viral Infections. Front Immunol (2017) 0.75
NK cell recognition. Annu Rev Immunol (2005) 14.40
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods (2004) 6.89
Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood (2004) 3.36
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol (2005) 2.54
Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet (2004) 2.54
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis (2006) 2.49
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood (2005) 2.40
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol (1997) 1.78
Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62
Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum Immunol (2005) 1.54
Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat Immunol (2006) 1.23
Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS (2005) 1.18
Modulation of expression of the MHC class I-binding natural killer cell receptors, and NK activity in relation to viral load in HIV-infected/AIDS patients. J Med Virol (2001) 1.03
The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Eur J Immunol (2005) 1.02
NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol (2002) 1.01
Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol Immunol (2004) 0.97
Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin Exp Immunol (2003) 0.92
Cytomegalovirus seroconversion as a cofactor for progression to AIDS. AIDS (2001) 0.87
The time relations of the photo-electric changes in the eyeball of the frog. J Physiol (1903) 31.79
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
The delay of the electrical response of nerve to a second stimulus. J Physiol (1910) 9.35
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature (1987) 4.66
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet (1992) 3.43
T-cell receptor variable gene products and early HIV-1 infection. Lancet (1992) 3.20
Sputum induction for diagnosis of Pneumocystis carinii pneumonia. Lancet (1989) 3.15
Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med (1987) 3.02
HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet (1993) 2.71
Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature (1990) 2.65
Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood (2001) 2.57
HIV-related lung cancer -- a growing concern? Int J STD AIDS (2003) 2.51
Gastrointestinal manifestations of HIV infection. Lancet (1996) 2.38
Temperature and Excitability. J Physiol (1896) 2.21
Cytotoxic lymphocytes from rats depleted of thymus processed cells. Nat New Biol (1971) 2.02
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J Virol (2001) 1.92
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91
The time-relations of the photo-electric changes produced in the eyeball of the frog by means of coloured light. J Physiol (1904) 1.88
Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect (2004) 1.79
Impact of HIV infection on mortality in young men in a London health authority. BMJ (1992) 1.78
Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum Retroviruses (1998) 1.73
Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res (1998) 1.70
Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer (2000) 1.66
Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis (2000) 1.66
Fluconazole resistant candida in AIDS. J Infect (1991) 1.64
Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut (1985) 1.64
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet (1995) 1.62
Managing tuberculosis and HIV infection. BMJ (1992) 1.56
Emergency laparotomy in patients with AIDS. Br J Surg (1991) 1.53
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood (2000) 1.52
A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol (1993) 1.48
Note on the so-called Tendon Reflex. J Physiol (1896) 1.46
The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol (2009) 1.46
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. HIV Med (2010) 1.45
Mucin secretion in inflammatory bowel disease: correlation with disease activity and dysplasia. Gut (1982) 1.43
Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut (1999) 1.42
"I plan to have the HIV test"--predictors of testing intention in women attending a London antenatal clinic. AIDS Care (1993) 1.40
The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer (1996) 1.40
Small-bowel mucosa in asymptomatic children with celiac disease. Mucosal changes with gluten-free diets. Am J Dis Child (1981) 1.39
Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol (2007) 1.39
Eating disorders in men with HIV infection. Br J Psychiatry (1992) 1.39
The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol (1981) 1.37
Meeting review: the Second meeting on the Critical Assessment of Techniques for Protein Structure Prediction (CASP2), Asilomar, California, December 13-16, 1996. Fold Des (1997) 1.36
Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS (1998) 1.35
Oligodeoxyribonucleoside methylphosphonates. NMR and UV spectroscopic studies of Rp-Rp and Sp-Sp methylphosphonate (Me) modified duplexes of (d[GGAATTCC])2. Nucleic Acids Res (1987) 1.31
Morphological and mucus secretion criteria for differential diagnosis of solitary ulcer syndrome and non-specific proctitis. J Clin Pathol (1982) 1.31
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med (2007) 1.30
Whose health is it? Views about decision-making and information-seeking from people with HIV infection and their professional carers. AIDS Care (1994) 1.30
Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol (1992) 1.29
The electrical response of nerve to two stimuli. J Physiol (1899) 1.27
Severe exercise hypoxaemia with normal or near normal X-rays: a feature of Pneumocystis carinii infection. Lancet (1988) 1.24
The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans (1992) 1.23
Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med (2005) 1.22
Summary of the II International Symposium on Cytomegalovirus. Antiviral Res (1998) 1.21
Contamination of endoscopes used in AIDS patients. Lancet (1989) 1.21
Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol (2009) 1.20
TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med (2003) 1.20
Candida and AIDS: evidence for protective antibody. Lancet (1988) 1.20
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A (1990) 1.19
Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer (2000) 1.17
A questionnaire survey of stress and bullying in doctors undertaking research. Postgrad Med J (2004) 1.16
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS (1996) 1.16
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med (2009) 1.14
On the Electrical Organ of the Skate. J Physiol (1888) 1.13
Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses (1999) 1.13
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med (2006) 1.13
Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res Hum Retroviruses (1994) 1.12
Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS (1999) 1.12
Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad Med J (2005) 1.12
Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses. J Immunol (1995) 1.12
Assessment of the response to chemotherapy in oesophageal cancer. Eur J Cardiothorac Surg (1991) 1.12
Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer (2000) 1.11
Functional roles of histidine and tyrosine residues in the H(+)-peptide transporter PepT1. Biochem Biophys Res Commun (2000) 1.10
The submaximal electrical response of nerve to a single stimulus. J Physiol (1902) 1.09
Testing for HIV in the antenatal clinic: the views of midwives. AIDS Care (1992) 1.09
Symmetry of H+ binding to the intra- and extracellular side of the H+-coupled oligopeptide cotransporter PepT1. J Biol Chem (1997) 1.09
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med (2008) 1.09
hPepT1-mediated epithelial transport of bacteria-derived chemotactic peptides enhances neutrophil-epithelial interactions. J Clin Invest (1998) 1.08
A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. AIDS (2001) 1.08
HLA-C and guttate psoriasis. Br J Dermatol (2000) 1.08
Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). HIV Med (2013) 1.07
Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol (1999) 1.07
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat (2009) 1.07
On the Electrical Organ of the Skate: Part II. J Physiol (1889) 1.06